Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction
Douglas L. Mann, Stephen J. Greene, Michael M. Givertz, Justin Vader, Randall C. Starling, Andrew P. Ambrosy, Palak Shah, Steven E. McNulty, Claudius Mahr, Divya Gupta, Margaret M. Redfield, Anuradha Lala, Gregory D. Lewis, Selma F. Mohammed, Nisha A. Gilotra, Adam D. DeVore, Eiran Z. Gorodeski, Patrice Desvigne‐Nickens, Adrian F. Hernandez, Eugene Braunwald
Topics & Concepts
SacubitrilHeart failureValsartanMedicineEjection fractionNatriuretic peptideInternal medicineTolerabilityClinical endpointCardiologyEnalaprilAngiotensin IIAngiotensin receptorSacubitril, ValsartanAngiotensin-converting enzymeRandomized controlled trialAdverse effectBlood pressureHeart Failure Treatment and ManagementCardiovascular Function and Risk FactorsMechanical Circulatory Support Devices